ResearchAlphaThe ten biomedical papers each week most likely to matter to a listed company, ranked by a Market Sensitivity Score. Educational content, not investment advice.https://researchalpha.org/enIssue 01 — Three device trials returned null results in one week and the strongest positive readings came from a sham comparison that failedhttps://researchalpha.org/issues/2026-09-11/https://researchalpha.org/issues/2026-09-11/Cardiology dominated the week and most of it went against the devices. A sham-controlled trial of atrial fibrillation ablation, a national trial of targeted lead placement, and a transcatheter valve anticoagulation study all reported results that make existing practice harder to defend rather than easier. The clearest positive signals came from a lipid-lowering mortality analysis and a phase 3 in HER2-positive breast cancer.Fri, 11 Sep 2026 12:00:00 GMTdevicesoncologydiagnosticspharma